Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

INTRODUCTION: Once-weekly semaglutide 1 mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than the GLP-1 RA once-daily liraglutide 1.2 mg in the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Adv Ther
Egile Nagusiak: Johansen, Pierre, Chubb, Barrie, Hunt, Barnaby, Malkin, Samuel J. P., Sandberg, Anna, Capehorn, Matthew
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467468/
https://ncbi.nlm.nih.gov/pubmed/32306244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01337-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak